Cobalamin

Summary

Cobalamin (CHEMBL4297272) is a phase-3 clinical-stage small molecule; indicated across 1 condition including non-small cell lung carcinoma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 1 condition
• Clinical trials: 3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297272
Name	Cobalamin
Type	Small molecule
Max phase	3

Also known as: Cobalamin, COBALAMIN

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
non-small cell lung carcinoma	3	MONDO:0005233	EFO:0003060

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE2/PHASE3	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03071666	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING	Vitamin B12 Supplementation During Pregnancy on Cognitive Development
NCT05096663	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING	Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
NCT03790345	PHASE2/PHASE3	UNKNOWN	Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).